


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A method of stereospecifically preparing a 3 β -hydroxy-5 β -H steroidal sapogenin of the formula



wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈ and R₉ are, independently of each other, H, C₁₋₄ alkyl, OH, or OR (where R = C₆₋₁₂ aryl or C₁₋₄ alkyl), or R₅ and R₆ together may represent a =O (carbonyl) or protected carbonyl group, the stereochemistry at carbon centre 3 can be either R or S, and R₁₀ represents β -OH, an β -O-linked sugar group or any β organic ester group, which comprises reducing a 3-keto-5 β -H steroidal sapogenin using a reducing agent comprising a hindered organoborane.

2. (original) A method according to claim 1, wherein the reducing agent is a hindered organoborane reagent in which organic groups contain more than two carbon atoms and the sapogenin obtained is predominantly a 3 β -hydroxy, 5 β -H-sapogenin.
3. (previously presented) A method according to claim 1, wherein hindered organoborane is selected from lithium tri-sec-butylborohydride, potassium tri-sec-butylborohydride, sodium tri-sec-butylborohydride, lithium trisiamylborohydride, potassium trisiamylborohydride, potassium triphenylborohydride and lithium triphenylborohydride.
4. (currently amended) A method according to claim 3, wherein the hindered organoborane is lithium tri-sec-butylborohydride.
5. (cancelled)
6. (previously presented) A method according to claim 1, wherein the molar ratio of the predominant sapogenin obtained to the alternative 3-epimer, is at least about 10:1.
7. (original) A method according to claim 6, wherein the ratio is at least about 15:1.
8. (previously presented) A method according to claim 1, when performed in an organic solvent selected from tetrahydrofuran, toluene, *tert*-butyl methyl ether, diethoxymethane, 1,4-dioxan, 2-methyltetrahydrofuran and any mixture thereof.

9. (original) A method according to claim 8, wherein the organic solvent consists essentially of tetrahydrofuran.
10. (original) A method according to claim 8, wherein the organic solvent consists essentially of toluene.
11. (original) A method according to claim 8, wherein the organic solvent consists essentially of 1,4-dioxan.
12. (currently amended) A method according to claim 8, wherein the organic solvent consists essentially of 2-methyltetrahydrofuran.
13. (cancelled)
14. (previously presented) A method according to claim 13, wherein the sapogenin is selected from sarsasapogenin, smilagenin, and esters thereof.
15. (currently amended) A method according to claim 1, wherein the 3-[]keto, 5 β -H steroidal sapogenin starting material is prepared by heterogeneous catalytic hydrogenation of a corresponding $\Delta[4]^4$, 3-keto steroidal sapogenin to convert the $\Delta[4]^4$, 3-keto steroidal sapogenin at least predominantly to the said 5 β -H, 3-ketone.
16. (original) A method according to claim 15, wherein the heterogeneous catalytic hydrogenation is performed using hydrogen and a palladium catalyst in an organic solvent.

17. (original). A method according to claim 16, wherein the palladium catalyst is present on a support.
18. (currently amended) A method according to claim 15, wherein the $\Delta[4]^4$, 3-keto steroidal sapogenin is diosgenone.
19. (currently amended) A method according to claim 18, wherein the diosgenone is obtained by oxidation of diosg.
20. (currently amended) A method for the conversion of a 3-hydroxy-activated derivative of 3α -hydroxy- 5β -H steroidal sapogenins ~~and derivatives thereof~~ to 3β -hydroxy- 5β -H steroidal sapogenins ~~and derivatives thereof~~, which comprises contacting a 3-hydroxy-activated derivative of a 3α -hydroxy- 5β -H steroidal sapogenin with a nucleophile under conditions favouring nucleophilic substitution with inversion at the 3-position, ~~with optional subsequent adjustment of the 3-substituent as desired.~~
21. (original) A method according to claim 20, wherein the reaction is performed according to the Mitsunobu reaction protocol, to yield an ester derivative of the 3β -hydroxy- 5β -H steroidal sapogenin.
22. (original) A method according to claim 20, wherein the activated derivative of the sapogenin is an organic sulphonated derivative.
23. (original) A method for the synthesis of smilagenin, comprising catalytic hydrogenation of diosgenone followed by reduction of the resulting 3-keto, 5β -H steroidal sapogenin using a hindered organoborane.

24. (currently amended) A method for the synthesis of epismilagenin, comprising catalytic hydrogenation of diosgenone followed by reduction of the resulting 3-keto,5 β -H steroidal sapogenin using an organo-alumino[-.]hydride.
25. (previously presented) A method according to claim 20, wherein a sapogenin initially formed is subsequently converted to a pro-drug form thereof or to another physiologically acceptable form thereof.
26. (previously presented) A method according to claim 2, wherein the hindred organoborane is an alkali metal tri-alkyl or tri-aryl borohydride reducing agent.
27. (currently amended) A method according to any one of claims 20 to 22, wherein the 3-hydroxy-activated derivative of the 3 α -hydroxy-5 β -H steroidal sapogenin is prepared by reducing a 3-keto-5 β -H steroidal sapogenin using a reducing agent comprising an organoborane including organic groups having up to two carbon atoms or an organo-aluminum hydride, with subsequent conversion of the resultant 3 α -hydroxy -5 β -H steroidal sapogen into its 3-hydroxy-activated derivative.
28. (currently amended) A method according to claim 27, wherein the organo-aluminum hydride is lithium tri-tert-butoxyaluminumhydride.
29. (currently amended) A method according to claim 27~~28~~, wherein the organoborane is lithium triethylborohydride.

30. (currently amended) A method according to ~~any one of~~ claims 27 ~~to 29~~, wherein the 3 α -hydroxy-5 β -H steroidal sapogenin and derivatives thereof produced in the reduction are selected from epilsarsasapogenin, epismlagenin and esters thereof.
31. (currently amended) A method according to ~~any one of~~ claims 20 ~~to 22 and 27 to 29~~, wherein the 3 β -hydroxy-5 β -H steroidal sapogenin and derivatives thereof produced in the conversion are selected from ~~from~~ sarsasapogenin, smilagenin and esters thereof.
32. (currently amended) A method according to any one of claims 22 to 25, wherein the 3-keto-5 β -H steroidal sapogenin is prepared by heterogeneous catalytic hydrogenation of a corresponding $\Delta[4]^4$, 3-keto steroidal sapogenin to convert the $\Delta[4]^4$, 3-keto steroidal sapogenin at least predominantly to the said 5 β -H, 3-ketone.
33. (currently amended) A method according to claim ~~32~~ 33 ~~or claim 34~~, wherein the $\Delta[4]^4$, 3-keto steroidal sapogenin is diosgenone, which is obtained by oxidation of diosgenin.
34. (new) A method according to claim 1, wherein a sapogenin initially formed is subsequently converted to a pro-drug form thereof or to another physiologically acceptable form thereof.